Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck
- 1 December 2004
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 40 (18) , 2748-2752
- https://doi.org/10.1016/j.ejca.2004.08.024
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancersInvestigational New Drugs, 2004
- Clinical Prognostic Factors for Patients with Recurrent Head and Neck Cancer: Implications for Randomized TrialsOncology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 2000